This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by University Hospital, Angers.
Recruitment status was:  Recruiting
French Innovative Leukemia Organisation
Information provided by:
University Hospital, Angers Identifier:
First received: September 12, 2005
Last updated: October 27, 2005
Last verified: September 2005

Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients:

  1. A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
  2. The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis.

The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival.

Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.

Condition Intervention
Adult Acute Lymphoblastic Leukemia Procedure: DNA Index Procedure: S-Phase% Procedure: CD45 expression Procedure: P16 metabolic way

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial

Resource links provided by NLM:

Further study details as provided by University Hospital, Angers:

Estimated Enrollment: 400
Study Start Date: November 2003
Estimated Study Completion Date: September 2005

Ages Eligible for Study:   15 Years to 59 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All GRAALL 2003 and 2005 enrolled patients with available frozen blast cells

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00188084

Contact: Agnès F CHASSEVENT, PhD 33-(0)2-41-35-27-00

CRLCC Centre Paul Papin Recruiting
Angers, France, 49933
Contact: Agnès F CHASSEVENT, PhD    33-(0)2-41-35-27-00   
Sub-Investigator: Mathilde HUNAULT-BERGER, MD,PhD         
Sub-Investigator: Martine FFrench, MD,PhD         
Sub-Investigator: Marina Lafage-Pochitaloff, MD,PhD         
Sub-Investigator: Françoise HUGUET, MD         
Sponsors and Collaborators
University Hospital, Angers
French Innovative Leukemia Organisation
Principal Investigator: Laurence M Baranger, MD University Hospital, Angers
  More Information Identifier: NCT00188084     History of Changes
Other Study ID Numbers: PHRC03-02
GOELAMS 271-003
Study First Received: September 12, 2005
Last Updated: October 27, 2005

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on June 22, 2017